Tarlatamab for carcinoma, neuroendocrine

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 10 Feb 2025: Trial registered, NCT06816394
  2. 25 Mar 2025: Trial registered, NCT06893783
  3. 2 Sep 2025: Trial started, NCT06893783
  4. 1 Jan 2026: Trial started, NCT06816394

The trials

NCT06816394: Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)

State
Under way
Phase
Phase 2
People
32 planned
Started
1 Jan 2026
Primary completion
31 Dec 2027
Arms
Tarlatamab
Results
None posted
  1. 10 Feb 2025: Trial registered
  2. 1 Jan 2026: Trial started

NCT06893783: Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma Patients

State
Under way
Phase
Phase 2
People
60 planned
Started
2 Sep 2025
Primary completion
30 Apr 2029
Arms
All patient
Results
None posted
  1. 25 Mar 2025: Trial registered
  2. 2 Sep 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.